338 related articles for article (PubMed ID: 24884578)
1. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
Stryjewski ME; Lentnek A; O'Riordan W; Pullman J; Tambyah PA; Miró JM; Fowler VG; Barriere SL; Kitt MM; Corey GR
BMC Infect Dis; 2014 May; 14():289. PubMed ID: 24884578
[TBL] [Abstract][Full Text] [Related]
2. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
Corey GR; Rubinstein E; Stryjewski ME; Bassetti M; Barriere SL
Clin Infect Dis; 2015 Mar; 60(5):787-96. PubMed ID: 25472944
[TBL] [Abstract][Full Text] [Related]
3. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens.
Rubinstein E; Lalani T; Corey GR; Kanafani ZA; Nannini EC; Rocha MG; Rahav G; Niederman MS; Kollef MH; Shorr AF; Lee PC; Lentnek AL; Luna CM; Fagon JY; Torres A; Kitt MM; Genter FC; Barriere SL; Friedland HD; Stryjewski ME;
Clin Infect Dis; 2011 Jan; 52(1):31-40. PubMed ID: 21148517
[TBL] [Abstract][Full Text] [Related]
4. Telavancin for refractory methicillin-resistant Staphylococcus aureus bacteremia and infective endocarditis.
Ruggero MA; Peaper DR; Topal JE
Infect Dis (Lond); 2015 Jun; 47(6):379-84. PubMed ID: 25746601
[TBL] [Abstract][Full Text] [Related]
5. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
Stryjewski ME; O'Riordan WD; Lau WK; Pien FD; Dunbar LM; Vallee M; Fowler VG; Chu VH; Spencer E; Barriere SL; Kitt MM; Cabell CH; Corey GR;
Clin Infect Dis; 2005 Jun; 40(11):1601-7. PubMed ID: 15889357
[TBL] [Abstract][Full Text] [Related]
6. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study.
Stryjewski ME; Chu VH; O'Riordan WD; Warren BL; Dunbar LM; Young DM; Vallée M; Fowler VG; Morganroth J; Barriere SL; Kitt MM; Corey GR;
Antimicrob Agents Chemother; 2006 Mar; 50(3):862-7. PubMed ID: 16495243
[TBL] [Abstract][Full Text] [Related]
7. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
Sandrock CE; Shorr AF
Clin Infect Dis; 2015 Sep; 61 Suppl 2():S79-86. PubMed ID: 26316561
[TBL] [Abstract][Full Text] [Related]
8. Telavancin.
Lyseng-Williamson KA; Blick SK
Drugs; 2009; 69(18):2607-20. PubMed ID: 19943710
[TBL] [Abstract][Full Text] [Related]
9. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
Nannini EC; Corey GR; Stryjewski ME
Expert Rev Anti Infect Ther; 2012 Aug; 10(8):847-54. PubMed ID: 23030322
[TBL] [Abstract][Full Text] [Related]
10. The role of telavancin in the treatment of MRSA infections in hospital.
Bassetti M; Mikulska M; Righi E; Nicolini L; Viscoli C
Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
[TBL] [Abstract][Full Text] [Related]
11. Telavancin for refractory MRSA bacteraemia in intermittent haemodialysis recipients.
Britt NS; Tirmizi S; Ritchie DJ; Topal JE; McManus D; Nizet V; Casabar E; Sakoulas G
J Antimicrob Chemother; 2018 Mar; 73(3):764-767. PubMed ID: 29244141
[TBL] [Abstract][Full Text] [Related]
12. Telavancin: a review of its use in patients with nosocomial pneumonia.
Scott LJ
Drugs; 2013 Nov; 73(16):1829-39. PubMed ID: 24190596
[TBL] [Abstract][Full Text] [Related]
13. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms.
Stryjewski ME; Graham DR; Wilson SE; O'Riordan W; Young D; Lentnek A; Ross DP; Fowler VG; Hopkins A; Friedland HD; Barriere SL; Kitt MM; Corey GR;
Clin Infect Dis; 2008 Jun; 46(11):1683-93. PubMed ID: 18444791
[TBL] [Abstract][Full Text] [Related]
14. Comparative activities of telavancin combined with nafcillin, imipenem, and gentamicin against Staphylococcus aureus.
Leonard SN; Supple ME; Gandhi RG; Patel MD
Antimicrob Agents Chemother; 2013 Jun; 57(6):2678-83. PubMed ID: 23545527
[TBL] [Abstract][Full Text] [Related]
15. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
Laohavaleeson S; Kuti JL; Nicolau DP
Expert Opin Investig Drugs; 2007 Mar; 16(3):347-57. PubMed ID: 17302529
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of telavancin in a murine model of bacteraemia induced by methicillin-resistant Staphylococcus aureus.
Reyes N; Skinner R; Benton BM; Krause KM; Shelton J; Obedencio GP; Hegde SS
J Antimicrob Chemother; 2006 Aug; 58(2):462-5. PubMed ID: 16735425
[TBL] [Abstract][Full Text] [Related]
17. Real-world use of telavancin in the treatment of osteomyelitis.
Saravolatz LD; Cleveland KO; Rikabi K; Hassoun A; Reilly J; Johnson LB; Spak C; Valenti S; Szpunar S
Diagn Microbiol Infect Dis; 2019 Oct; 95(2):185-190. PubMed ID: 31256939
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model.
Hegde SS; Difuntorum S; Skinner R; Trumbull J; Krause KM
J Antimicrob Chemother; 2009 Apr; 63(4):763-6. PubMed ID: 19155225
[TBL] [Abstract][Full Text] [Related]
19. Heart transplantation in a patient with heteroresistant vancomycin-intermediate Staphylococcus aureus ventricular assist device mediastinitis and bacteremia.
Swartz TH; Huprikar S; Labombardi V; Pinney S; Anyanwu A; Lee M; Patel G
Transpl Infect Dis; 2013 Oct; 15(5):E177-81. PubMed ID: 23902131
[TBL] [Abstract][Full Text] [Related]
20. Telavancin for the treatment of methicillin-resistant Staphylococcus aureus bone and joint infections.
Harting J; Fernandez F; Kelley R; Wiemken T; Peyrani P; Ramirez J
Diagn Microbiol Infect Dis; 2017 Dec; 89(4):294-299. PubMed ID: 29137718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
